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Abstract 
Background: Congenital cytomegalovirus (CMV) is the most common congenital infection globally, however 
information about CMV is not routinely included in antenatal education in the United Kingdom. This feasibility study 
aimed to gather the essential data needed to design and power a large randomised controlled trial (RCT) to investi-
gate the efficacy of a digital intervention in reducing the risk of CMV acquisition in pregnancy. In order to do this, we 
carried out a single-centre RCT, which explored the knowledge, attitudes and risk reduction behaviours in women in 
the intervention and treatment as usual groups, pre- and post-intervention.
Methods: CMV seronegative women living with a child less than four years old, receiving antenatal care at a single 
UK tertiary centre, were randomised to the digital intervention or ‘treatment as usual’ groups. Participants completed 
questionnaires before the digital intervention and after and at 34 gestational weeks, and responses within groups and 
between groups were compared using tailored randomisation tests. CMV serology was tested in the first trimester 
and at the end of pregnancy.
Results: Of the 878 women screened, 865 samples were analysed with 43% (n = 372) being CMV seronegative and 
therefore eligible to take part in the RCT; of these, 103 (27.7%) women were enrolled and 87 (84%) of these completed 
the study. Most participants (n = 66; 64%) were unfamiliar with CMV at enrolment, however at 34 gestational weeks, 
women in the intervention group (n = 51) were more knowledgeable about CMV compared to the treatment as usual 
group (n = 52) and reported engaging in activities that may increase the risk of CMV transmission less frequently. 
The digital intervention was highly acceptable to pregnant women. Overall, four participants seroconverted over the 
course of the study: two from each study group.
Conclusions: A large multi-centre RCT investigating the efficacy of a CMV digital intervention is feasible in the 
United Kingdom; this study has generated essential data upon which to power such a study. This single-centre 
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Background
Congenital cytomegalovirus (CMV) is the commonest 
congenital infection globally and has a birth prevalence 
of 0.3–1% [1–3]. Congenital CMV (cCMV) can occur fol-
lowing the first infection with CMV during pregnancy 
(primary CMV infection), after reactivation of CMV 
acquired previously or following infection with a differ-
ent strain of CMV (secondary CMV infection). The risk 
of transmission to the fetus is significantly higher in pri-
mary infection than in secondary infection [4]. Despite 
this, globally more infants with cCMV are born to moth-
ers with secondary infection than with primary infection 
due to the high CMV seroprevalence in many parts of 
the world [4]. CMV is transmitted through contact with 
infected bodily fluids and those people who have a child, 
or children, already are at increased risk of acquiring the 
infection, primarily through contact with infected saliva 
or urine from their young child [5].
The clinical spectrum of cCMV at birth is wide: around 
85% of infants will be ‘asymptomatic’ and 15% will have 
symptoms at birth [6]. Long term sequelae occur in 
about 40–60% of babies who are symptomatic at birth, 
and 10–15% of babies who are asymptomatic [2]. The 
most common long-term effect of cCMV is sensorineural 
hearing loss, with cCMV being the most frequent non-
genetic cause of sensorineural hearing loss and the only 
preventable cause [7]. cCMV represents a significant 
public health problem, but there are currently no licensed 
vaccines and no routinely recommended treatments for 
antenatal CMV infection. The United Kingdom (UK) cur-
rently has no national screening programme for CMV for 
pregnant women or infants, [8] and women are not rou-
tinely counselled about CMV risk reduction measures.
Antenatal education about CMV risk reduction may 
provide a significant opportunity to reduce CMV infec-
tion in pregnancy and consequently reduce the inci-
dence of cCMV. In a recent systematic review, seven 
studies were identified which investigated preventative 
hygiene-based interventions in pregnancy or in women 
of child-bearing age [9]. This concluded that hygiene-
based interventions in pregnancy could play a useful role 
in primary prevention of CMV infection in pregnancy, 
however the studies were too heterogeneous in terms of 
study population, intervention and outcome to form firm 
conclusions on the relative impact of such interventions. 
Additionally, the majority of interventions would not be 
easily translatable to routine antenatal care, without the 
provision of significant additional resources.
A randomised controlled trial (RCT) using an accepta-
ble educational intervention—which can be subsequently 
integrated into routine care in the UK—is urgently 
needed.
RACE FIT (Reducing Acquisition of CMV through 
antenatal Education) was designed to inform the feasi-
bility and design of a large-scale RCT in a UK setting to 
investigate the efficacy of the educational intervention 
on the risk of acquiring CMV infection in pregnancy. It 
was designed in two phases, the first of these involved in-
depth interviews with pregnant women and the families 
of children affected by cCMV. These interviews explored 
their knowledge and attitudes about CMV, and perspec-
tives on infection prevention in pregnancy, in order to 
prioritise themes to include in the intervention [10, 11]. 
From these findings, a script was produced and the digi-
tal intervention developed as a short educational film 
through an iterative process involving review by pregnant 
or recently pregnant women, families affected by CMV, 
and knowledge experts. The aim of this second phase of 
RACE FIT was to test the digital intervention in a feasi-
bility study where women were randomised to the inter-
vention or treatment as usual groups, in order to provide 
information about recruitment and conduct of a future 
trial, assess the acceptability of the educational interven-
tion and explore changes in knowledge, attitudes and 
behaviours in the two groups. We also determined CMV 
seroconversion in both groups. The overarching aim was 
to inform the feasibility and design of a large-scale ran-
domised controlled trial (RCT) in a UK setting to inves-
tigate the efficacy of the digital, antenatal educational 
intervention on the risk of acquiring CMV infection in 
pregnancy.
Methods
Study setting and screening
We recruited all participants from a single teaching hos-
pital in an ethnically diverse area of South-West Lon-
don. We approached women in their first trimester of 
pregnancy who were attending antenatal clinics between 
September 2018 and September 2019; women who lived 
with a child or children less than four years of age were 
asked for their consent for CMV serology to be under-
taken on an additional blood sample. All women in the 
feasibility RCT demonstrates that a digital educational intervention is associated with increase in knowledge about 
CMV and can result in behaviour change which may reduce the risk of CMV acquisition in pregnancy.
Trial registration: Clinicaltrials.gov, NCT03 511274, Registered 27.04.18, http:// www. Clini caltr ials. gov
Keywords: Cytomegalovirus, Congenital infection, Pregnancy, Antenatal education, Feasibility
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study were tested for both CMV IgG and IgM antibodies. 
Women who were seronegative (no evidence of previous 
CMV infection; IgG negative) were invited to take part in 
the RCT; those who were CMV IgG positive and CMV 
IgM negative were not eligible to take part and those 
who were CMV IgM positive had additional serology 
undertaken including CMV IgG avidity testing. Women 
with serological evidence of recent CMV infection were 
referred for counselling and further investigation under 
an established routine clinical pathway.
Eligibility
Women were considered to be eligible for the RCT if they 
were aged over 18, pregnant, willing and able to provide 
informed consent, seronegative for CMV, having no doc-
umented immunodeficiency, living with at least one child 
aged less than four and willing to be followed up until 
delivery.
Randomisation
After providing informed consent, participants were ran-
domised in a 1:1 ratio to the intervention or treatment 
as usual group using the randomisation service provided 
by the King’s College Clinical Trials Unit. The randomi-
sation sequence was computer generated. Neither the 
participant nor the researcher was blinded to group 
allocation.
Study materials
Participants who were randomised to the intervention 
group watched the educational film—developed in phase 
one—at their first study visit. The film was made up of 
three parts: a presentation of facts about CMV, includ-
ing prevalence and routes of transmission; families of 
affected children telling their stories; and advice provided 
about how the risk of infection could be reduced (Sup-
plementary material 1). Participants in the treatment as 
usual group viewed a series of slides about influenza vac-
cination in pregnancy. Influenza vaccination is routinely 
recommended in pregnancy in the UK and all pregnant 
women receive information about this as part of routine 
care.
Study design
The study was approved by the NHS Health Research 
Authority and South-Central Oxford Research Ethics 
Committee (16/SC/0683).
Women had their first study visit at home or in clinic 
before 16 gestational weeks. Following informed writ-
ten consent, all participants completed a questionnaire 
(Supplementary material 2) and were then randomised 
into either the intervention or treatment as usual groups. 
Participants then either watched the digital educational 
intervention (intervention group) or reviewed a series of 
slides about influenza vaccination in pregnancy (treat-
ment as usual group) and then immediately completed a 
second questionnaire about the materials they had been 
presented with (Supplementary material 3 and 4). At 34 
gestational weeks, participants completed a final online 
questionnaire (Supplementary material 5 and 6). Within 
two weeks of delivery a blood sample was obtained from 
all participating mothers. This was tested for CMV spe-
cific IgG and IgM antibody to assess for seroconversion 
over the study period. Clinical follow up was organised 
for those participants and their infants who were found 
to have seroconverted since initial screening.
Measures.
Participant demographics
Information was collected about age, marital status, eth-
nicity, length of residence in the UK, qualifications, num-
ber of previous pregnancies, number of children under 
four years of age and whether participants worked regu-
larly with children as part of their job.
Familiarity with CMV
At baseline, participants indicated how familiar they were 
with a range of conditions affecting newborns, including 
CMV, and about how common they thought these condi-
tions were [12].
Response to materials
At the first study visit, the intervention group provided 
their responses to the educational film by indicating their 
level of agreement with a range of statements.
For the following domains, participants in both 
groups were asked for their responses at baseline and at 
34 weeks:
Knowledge of CMV:
Participants were asked to specify their level of agree-
ment with 12 statements about CMV [12]. These 
included both true and false statements.
Perceived severity and susceptibility
Participants were asked to indicate their level of agree-
ment with statements about the severity of CMV and 
their perceived susceptibility to CMV.
Anxiety and depression scores
Participants were asked to indicate how they had been 
feeling recently using the Kessler Psychological Dis-
tress Scale [13] and the Edinburgh Postnatal Depression 
Scale [14].
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Daily activities
Participants were asked how often they engaged in a 
range of behaviours [12] relating to contact with a child’s 
saliva, urine or faeces. At 34 gestational weeks, partici-
pants were asked to indicate how hard it had been to 
make the suggested behavioural changes.
Laboratory methods
CMV IgM and IgG were measured using the Roche Elec-
sys assay (Roche, Switzerland), according to manufac-
turer’s instructions. For individuals who were found to 
be CMV IgM positive further testing was performed for 
IgG avidity using the VIDAS CMV IgG avidity 11 assay 
(Biomerieux, France).
Data collection and analysis
Study data were collected and managed using REDCap 
electronic data capture tools hosted at St George’s, Uni-
versity of London.
Statistical analyses
Data were graphically explored and summarised. Anxi-
ety and depression scores, which exhibited a wide range 
of values (additive scores), were treated as continuous 
data. Outcomes reflecting measurements for familiarity, 
attitudes, behaviour and knowledge were of ordinal type. 
Missing responses were assessed for each variable of 
interest. Both per-protocol (PP) and intention-to-treat 
(ITT) analyses were conducted [15]. Given the ran-
domisation, permutation tests have been conducted for 
between groups comparisons assuming that the missing 
observations were completely at random [15–19]. Similar 
assumptions were considered for within groups’ compar-
isons. The PP and ITT analyses did not show markable 
qualitative differences for any of the outcomes.
This study aimed to detect potentially important signals 
to be investigated in a larger trial and was not designed as 
a hypotheses testing study. Given the exploratory phase 
of this research, classical Bonferroni corrections for mul-
tiple outcome testing were not applied.
All analyses and graphics have been produced using 
STATA 16 (StataCorp. 2019.  Stata Statistical Software: 
Release 16. College Station, TX: StataCorp LLC).
Results
Screening for participation
A large number of women were approached about the 
study (n = 3975), of whom 878 (22%) had a blood sample 
taken for CMV serology, Fig. 1.
Fig. 1 CONSORT flow diagram. CMV Cytomegalovirus; FMU Fetal Medicine Unit
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The most common reason for ineligibility for blood 
sampling was not living with a child aged less than four 
(n = 2751; 88.8%).
Overall, 43% (n = 372) of participants were seronega-
tive and eligible to be approached about participation 
in the RCT and 57% (n = 493) of women were seroposi-
tive. Of all the women screened, ten (1.16%) had evidence 
indicating recent infection, within the last three months, 
and were referred to the Fetal Medicine Unit for further 
clinical investigation. Details of ethnicity were available 
for 532 women screened. The proportion of women who 
were seronegative varied by self-defined ethnicity: 61% 
White British (n = 172), 39% White Other (n = 32), 6% 
Black (n = 3), 22% South Asian (n = 21), 14% Asian Other 
(n = 2), 46% Mixed (n = 6).
Feasibility randomized controlled trial
Of the 372 women who were CMV seronegative, 103 
women consented to participate in the RCT (27.7%), of 
whom 87 (84%) participants completed the study (Fig. 1). 
Study completion was defined as collection of a final 
blood sample or completion of a 34-week questionnaire. 
Recruitment ended at the conclusion of the pre-defined 
recruitment period of 12  months. At that time, we had 
recruited about 25% of the initially planned recruitment 
number.
Participant characteristics
The demographic characteristics of the participants are 
shown in Table 1.
Familiarity with CMV and other conditions
On enrolment to the study, most participants who 
responded were unfamiliar with CMV; 64% (n = 66) of 
participants reported that they were ‘not at all familiar’ 
with CMV compared with 1% (n = 1) for Trisomy 21, 
9% for rubella (n = 9), 13% (n = 13) for listeria and 32% 
(n = 32) for toxoplasmosis. There was no evidence to 
suggest any difference between the distribution of the 
responses in the two randomisation groups (Supplemen-
tary material 7; Fig. 1).
Participants’ knowledge about CMV
Knowledge about how CMV is transmitted and what 
effect congenital CMV can have on infants was consist-
ent between randomisation groups, with no differences 
at baseline. At 34 gestational weeks, knowledge about 
CMV was significantly different between participants 
in the intervention group and participants in the treat-
ment as usual group; a higher proportion of participants 
in the intervention group correctly agreed that CMV 
can be spread through saliva and urine, and could cause 
hearing loss and adverse neurodevelopmental outcomes, 
Table 2. Within the intervention group, there was a sig-
nificant difference in knowledge about transmission of 
CMV and the potential consequences of congenital CMV 
for the infant or child, at baseline compared to 34 gesta-
tional weeks, Table  2. Knowledge about how CMV can 
be transmitted was also different at 34 gestational weeks 
compared to baseline in the treatment as usual group, 
however there was not a significant difference in knowl-
edge about the impact of CMV on hearing and develop-
ment in this group, suggesting the participants gained 
some knowledge about CMV during the study period, 
despite not being exposed to the intervention, Table 2.
Perception of severity and susceptibility
At baseline, participants’ perceptions about the severity 
of CMV and susceptibility to CMV were similar in the 
intervention and treatment as usual groups, Fig. 2. After 
the intervention (34 gestational weeks), a higher propor-
tion of participants in the intervention group were likely 
to consider CMV to be serious and themselves personally 
susceptible to CMV, and to agree that advice about CMV 
should be given to pregnant women, compared to before 
the intervention (at baseline), Fig. 2. In contrast, the atti-
tudes of pregnant women towards CMV in the treatment 
as usual group were similar at baseline and 34 gestational 
weeks, Fig. 2.
Risk behaviours for CMV
At baseline, participants in the treatment as usual and 
intervention groups reported similar engagement with 
activities which might expose them to saliva or urine of 
children, for example commonly reporting eating left-
over food from a child’s plate, Table 3. Within the inter-
vention group, women reported eating left-over food, 
drinking from a child’s cup or kissing their child directly 
on the lips, less frequently after the intervention com-
pared to before the intervention, Table 3. Differences in 
behaviours of women in the treatment as usual group 
were also observed between baseline and 34 gestational 
weeks, Table 3. Despite some differences in the frequency 
at which participants engaged in these activities in both 
groups, there was a difference between the two groups 
at 34 gestational weeks, with women in the intervention 
group reporting eating left-over food and kissing on the 
lips less frequently than women in the treatment as usual 
group, Table 3.
Acceptability of educational intervention
Participants in the intervention group responded posi-
tively to the educational film, reporting that they felt 
motivated to change activities and felt confident that they 
could do so and would recommend the film to friends, 
Table 4.
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Anxiety, depression
There were no significant differences observed between 
scores on the Kessler Psychological Distress Scale or 
the Edinburgh Postnatal Depression Scale between the 
intervention and treatment as usual groups at baseline 
or at 34 weeks (Supplementary material 8; table 1).
Seroconversion
Seroconversion between the end of the first trimester 
(baseline) and 34 gestational weeks was 4.55% in the 
intervention group and 4.65% in the treatment as usual 
group. There was one newborn infant, born to a mother 
in the intervention group who had seroconverted during 
Table 1 Demographic characteristics of participants
INT Intervention group; TAU Treatment As Usual group
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Table 2 Knowledge of CMV in participants at baseline and 34 weeks
CMV Cytomegalovirus; INT Intervention group; TAU Treatment As Usual group
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pregnancy, who tested CMV PCR positive in urine at 
birth and therefore had congenital infection. The infant 
had no clinical features of cCMV and no treatment was 
required. The infant remained well with no clinical fea-
tures of congenital CMV at 12 months of age.
Discussion
This feasibility study demonstrates that recruitment 
to a future randomised controlled trial investigating 
the efficacy of a film-based educational intervention in 
reducing the risk of acquiring CMV infection in preg-
nancy would be feasible and has generated essential 
data upon which to design and power a larger RCT. 
This single-centre randomised controlled trial has 
shown that digital antenatal education about CMV 
is acceptable and accessible to pregnant women and 
does increase knowledge about CMV, change attitudes 
towards personal susceptibility and severity, and that 
pregnant women were willing to adopt risk-reducing 
behaviour change to reduce exposure to saliva and 
urine of young children. A future large multi-centre 
randomised controlled trial would be needed to deter-
mine whether such changes in knowledge, attitudes and 
behaviour would have an impact on seroconversion 
in pregnancy and therefore prevention of congenital 
CMV.
In this feasibility study, we have been able to identify 
factors which would be crucial to the design of a multi-
centre randomised controlled trial. To determine the 
efficacy of an educational intervention, it is necessary to 
identify and enrol seronegative women in order to dem-
onstrate seroconversion – thus acquisition of infection. 
We have shown that testing for CMV serology is highly 
acceptable to pregnant women in the first trimester of 
pregnancy; 2.86% (n = 144) of women declined testing 
for CMV antibodies, suggesting that the vast majority of 
Fig. 2 Attitudes of pregnant women toward the severity of CMV and their susceptibility to CMV at baseline and 34 gestational weeks in the 
treatment as usual group and the intervention group. CMV Cytomegalovirus; INT Intervention group; TAU Treatment As Usual group; Intention to 
treat analyses between intervention and treatment as usual groups at baseline (pre-intervention) and at 34 weeks gestation (post-intervention) and 
within intervention and treatment as usual groups comparisons between baseline and 34 weeks gestation
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Table 3 Engagement with activities that potentially expose women to saliva or urine of children
INT Intervention group; TAU Treatment As Usual group; Intention to treat analysis between intervention and treatment as usual groups at baseline (pre-intervention) 
and at 34 gestational weeks (post-intervention) and within intervention and treatment as usual groups at baseline and 34 gestational weeks
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women would be willing to be screened for CMV infec-
tion in pregnancy, in the NHS setting, and is consistent 
with that reported in other studies [20].
Multiparous seronegative women who have young 
children are at the highest risk of acquiring infection 
and transmitting this to their fetus, therefore these 
women would be the target population for future stud-
ies. We have demonstrated the challenges in identifying 
and enrolling this target population. A large number of 
women were ineligible for the study (n = 2320; 58.4%) 
because they were primiparous (this was their first 
pregnancy) and of those who were multiparous, a further 
431 women were excluded because they did not have a 
child < 4  years of age. Together with the women who 
were ineligible for other reasons (n = 202) or for whom 
no sample was obtained (n = 13), only 878 (22%) of the 
3975 women approached had a blood sample for CMV 
screening obtained. These factors are critical to take into 
account when designing and assessing the feasibility of 
future studies.
Of the women who consented for CMV screening, 43% 
were seronegative and therefore at risk of primary CMV 
Table 4 Reported responses to the educational intervention from participants in the intervention group
INT Intervention group; CMV Cytomegalovirus
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infection and eligible for the study, and 57% of women 
were seropositive. The proportion of women who were 
seropositive varied considerably with ethnicity. The sero-
positivity in white women of 39% is similar to that seen 
in previous studies (45.9% Tookey, 1992; 49% Pembrey, 
2013) [21, 22]. However, we found lower seropositivity 
in women from South Asian ethnicity (78%) compared 
to that seen in the cohort of pregnant women in Brad-
ford (89%—98%) [22] and higher seropositivity in black 
women (94%) than has been observed in a population 
of women attending antenatal care in London in the 
1990s (77%) [21]. Both Tookey et al. and Pembrey et al. 
found place of birth, as well as ethnicity to be important 
in seroprevalence, with British born women less likely 
to be seropositive [21, 22]. We did not collect informa-
tion about place of birth and so were unable to investi-
gate this aspect. Because of the eligibility requirements of 
the studies being recruited for, we only screened women 
living with a child aged less than four years, which may 
mean that this population is not completely representa-
tive of the pregnant population as a whole, but does rep-
resent women who are likely to be at the highest risk of 
infection in pregnancy.
A total of ten women (1.16%) had evidence indicat-
ing recent primary CMV infection within the first tri-
mester of pregnancy, this is higher than that observed 
in an unselected population in a single centre in France 
(0.42% seroconversion) [20], but consistent with propor-
tions seen in a population of women in Italy who had a 
young child or worked with young children (1.2%) [23]. 
Although this is a small proportion of women, this results 
in a large number of infants born each year with CMV. 
Vertical transmission in the first trimester of pregnancy is 
estimated at 36.8% with nearly 20% of fetuses from these 
women showing evidence of being affected by CMV 
[24]. Without interventions to reduce the risk of acquisi-
tion of CMV or transmission of CMV, these infants will 
continue to acquire CMV and a significant proportion of 
them continue to suffer long term adverse sequelae as a 
result of congenital CMV infection.
As well as generating essential data to inform a future 
larger study, we have also been able to describe important 
differences in knowledge about CMV, perceived severity, 
susceptibility and CMV risk reducing behaviour of preg-
nant women in the two study groups before the interven-
tion in early pregnancy and at 34 gestational weeks. By 
collecting post-intervention data at 34 gestational weeks, 
we are able to show that these differences were evident 
even at the end pregnancy, suggesting that women were 
able to sustain these changes throughout pregnancy.
Before the intervention, most women were unfamiliar 
with CMV. Previous studies have also shown that only a 
minority of pregnant women have heard of CMV: 16% 
in an Australian study,[25] 18% in a Japanese study [26] 
and 20% in two separate studies in Singapore [27], and 
the US [28], and that the level of knowledge about CMV 
is less than for other conditions which affect newborn 
infants [25, 26, 28, 29]. Despite the fact that CMV is the 
most common congenital infection in the UK, pregnant 
women in our study were also less knowledgeable about 
CMV than other conditions affecting newborns. In our 
study, 34.7% of women reported being ‘somewhat’ or 
‘very’ familiar, a higher proportion than in other studies. 
This may reflect volunteer bias in which those individuals 
who are better informed about CMV are more likely to 
take part in research about it, or it may have been a prod-
uct of the screening process in which it was necessary to 
provide some information about CMV in the process of 
obtaining consent for serological screening.
Participants in the intervention group showed a greater 
awareness of the ways in which CMV can be transmitted 
and ways in which congenital CMV can affect children 
following the intervention, at 34 gestational weeks, com-
pared to those women in the treatment as usual group. 
This is in agreement with the study by Price et  al., who 
also included change in knowledge as an outcome follow-
ing an antenatal educational intervention [12].
The ultimate aim of a CMV educational intervention in 
pregnancy is not acquisition of facts, but rather to modify 
behaviours that would place a woman at increased risk 
of exposure to CMV. In agreement with other studies 
[12, 20, 23, 30–32], we found that an educational inter-
vention in pregnancy was associated with a reduction in 
the frequency of activities which could expose women to 
saliva and urine of young children, compared to before 
the intervention and compared to the treatment as usual 
group, specifically a reduction in participants eating left-
overs from their child’s plate and kissing their child on 
the lips. These behaviours have previously been identified 
as being most difficult to change [33]. These changes in 
reported behaviours may relate to the change in the per-
ception of severity and susceptibility which was seen in 
the intervention group; change in perception of severity 
of the condition and an individual’s susceptibility to it has 
been shown to be an important mediator of behaviour 
change [32].
As far as possible, we wanted to have a single interven-
tion early in pregnancy in order to create circumstances 
as similar as possible to clinical practice, and we there-
fore provided no reminders to participants about risk 
reduction, we did not ask them about their behaviours 
between the first appointment and the questionnaire at 
34 weeks and we did not use any objective measures of 
adherence which is in contrast to some other studies [30, 
31, 34]. Whilst all of these measures were important to 
our ultimate goal of investigating an intervention which 
Page 12 of 13Calvert et al. BMC Pregnancy Childbirth          (2021) 21:565 
would have clinical utility in a routine setting, there are 
also limitations associated with this approach. Self-
reported behaviour may not be the same as actual behav-
iour, especially when asking participants about their 
activities over a prolonged period. This may particularly 
be the case for those behaviours for which there is a per-
ceived ‘right’ answer, for example washing hands after 
changing a nappy. We were unable to completely simu-
late real life conditions; in order to screen for the serosta-
tus of potential participants it was necessary to provide 
some information about CMV which caused many of the 
participants to seek further information. This may have 
led to our whole study population being better informed 
about CMV than the general population and may have 
limited our ability to detect differences between the 
groups—although this would have led to an underestima-
tion of the effect of the intervention and if such an inter-
vention were used in routine care there might be an even 
greater impact on behaviours.
In this study we used a film as our educational inter-
vention that had been designed in partnership with 
pregnant women and families of affected children. The 
feedback we received from study participants suggests 
that this was highly accessible and acceptable to them. 
Importantly, participants in the intervention group had 
similar scores on a global measure of distress and on a 
screening tool designed to identify individuals at risk of 
perinatal depression compared to those in the treatment 
as usual group – both pre- and post-intervention.
This study confirmed a finding which has been shown 
in repeated studies which is that pregnant women want 
to know about CMV and are often shocked that this 
has not been discussed with them before [26, 27, 34]. 
This reinforces the importance of a future large trial to 
determine the efficacy of an educational intervention to 
reduce the risk of CMV acquisition in pregnancy and the 
optimal implementation strategy for CMV antenatal edu-
cation in routine clinical practice.
Conclusions
We have demonstrated that a randomised controlled trial 
of a film-based educational intervention is feasible in the 
UK and generated essential data upon which to power 
such studies. This single-centre randomised controlled 
trial has also shown that the intervention was associated 
with differences in knowledge, attitudes and behaviours 
before and after the intervention. This gives confidence 
that it may be possible to reduce the risk of acquisition of 
CMV in pregnancy using a film-based educational inter-
vention. The efficacy of this needs to be tested in a future 
multi-centre randomised controlled trial.
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